The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | N | Nervous system | |
| 2 | N02 | Analgesics | |
| 3 | N02A | Opioids | |
| 4 | N02AA | Natural opium alkaloids | |
| 5 | N02AA03 | Hydromorphone |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 20 mg |
| PAREN - Parenteral | 4 mg |
| RECTAL - Rectal | 4 mg |
| Active Ingredient | Description | |
|---|---|---|
| Hydromorphone |
Hydromorphone is an agonist of mu receptors. The pharmacological actions of hydromorphone and morphine do not differ significantly. Hydromorphone and related opioids produce their major effects on the central nervous system and bowel. Hydromorphone is indicated for the relief of severe pain in cancer. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| DILAUDID Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| JURNISTA Prolonged-release tablet | Marketing Authorisation Holder | MPI, EU: SmPC | |
| PALLADONE Prolonged release capsule | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| PALLADONE Solution for injection or infusion | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
